Treatment of metastatic breast cancer: second line and beyond.
about
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Progress in circulating tumor cell capture and analysis: implications for cancer managementMicroenvironmental regulation of therapeutic response in cancerMetastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin.Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents.Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells.Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?Breast carcinoma metastasis to the lacrimal gland: Two case reportsSafety and Efficacy of Tien-Hsien Liquid Practical in Patients with Refractory Metastatic Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IIa Trial.Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cellsHigh-cost imaging in elderly patients with stage IV cancer.Overweight and obesity predict better overall survival rates in cancer patients with distant metastases.Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome.Etirinotecan pegol for the treatment of breast cancer.Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).Efficacy and safety of doublet versus single agent as salvage treatment for metastatic breast cancer pretreated with anthracyclines and taxanes: a systematic review and meta-analysis.Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts.Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.Defining what matters most to patients.Improving patient care: expert nursing and service development.Current treatment of HER 2+ metastatic breast cancer.A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded studyDevelopment, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics AlgorithmPhase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
P2860
Q26745420-0BA904DC-CBA2-449E-BF53-4730EE0B37D1Q27025737-1DCD1C8C-37FA-46F7-97CD-B6913E54B9C8Q33654609-25F58142-1FA4-4D80-9CE2-5516DCE05CC7Q33744198-15A14DC2-DCA6-4A28-B1D9-2038A1EAFB49Q34080274-0B21F705-0517-4D31-9359-3B909759BFDEQ35065126-B11E42D6-C378-4720-898C-0A131555FA20Q35507680-802FCD6E-3E6E-4401-AAF2-32FA48C39DE1Q35820575-0EACF3CB-8687-42D7-AF1A-553C6A0445F3Q35870257-2EA41CE9-6F1D-4247-84D6-73D5631A9F20Q35876014-E2812206-48AE-41D5-9203-EE4559499312Q35902206-D1CC2008-64D5-4021-A701-71492329E826Q36457669-D6312D84-23AB-4D24-88F4-207F5F410D92Q36727374-A0BB80AE-3F06-4654-ABED-D679BB68EA29Q36797278-962D4FDB-7624-47FF-80FB-42E5DE28719CQ36836599-46742602-F69E-4FFA-85FB-A61876042323Q37236305-EA725F3A-B601-41B5-8E0B-D0F1C5B0DC14Q38091335-2F220ED7-136C-4C94-A281-B14CE4F9AF14Q38259259-DD156486-DBAA-4F88-B431-E77F226D38F0Q38381907-D96A2159-0F02-4382-B5A7-7BC834D71458Q38735361-8E0F792E-3AD4-40A2-9C58-FD57C60C757CQ38880515-5917DB04-196E-47CE-A72E-61EEC81CBDCCQ38917718-40842A4E-2C15-48AA-AE2A-DC28DA81882EQ39327842-FB400AE5-5D75-420E-9E6F-065F509B637DQ41280473-06F483D7-2537-456D-975E-B2F3E8B1080BQ45289630-0ED685A2-0543-45C4-BBE2-74D8E144FF5EQ47592237-0E4718FC-6FEB-4CED-BB7F-34C054076142Q47665955-68951F9A-3EDA-4A56-8BFB-0C6814871285Q49581531-DA961820-ED32-4B5F-A7A7-77BB25881321Q49581539-260B3D39-BD5D-4C88-B0CF-D91AEA0263A1Q50908788-9CBE103B-DEA0-4C22-BCA7-8B400D1783C5Q56523625-13D54D7A-C524-4814-8935-BDC0D342E861Q57114388-EE08117B-3EB6-4448-8FF7-FAC7E00A6D12Q57222268-1EEE4968-CC7B-4A74-892E-414167806FEF
P2860
Treatment of metastatic breast cancer: second line and beyond.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of metastatic breast cancer: second line and beyond.
@en
Treatment of metastatic breast cancer: second line and beyond.
@nl
type
label
Treatment of metastatic breast cancer: second line and beyond.
@en
Treatment of metastatic breast cancer: second line and beyond.
@nl
prefLabel
Treatment of metastatic breast cancer: second line and beyond.
@en
Treatment of metastatic breast cancer: second line and beyond.
@nl
P2860
P356
P1433
P1476
Treatment of metastatic breast cancer: second line and beyond.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDQ429
P577
2010-10-21T00:00:00Z